Table of Contents

1 Product Introduction and Overview

• 1.1 Product Definition
• 1.2 Product Specification
• 1.3 Global Market Overview
  • 1.3.1 Global Gastrointestinal Therapeutics Market Status and Forecast (2016-2027)
  • 1.3.2 Global Gastrointestinal Therapeutics Sales Value CAGR by Region
• 1.4 Market Drivers, Inhibitors
  • 1.4.1 Market Drivers
  • 1.4.2 Market Inhibitors
  • 1.4.3 COVID-19 Impact Analysis

2 Global Gastrointestinal Therapeutics Supply by Company

• 2.1 Global Gastrointestinal Therapeutics Sales Value by Company
• 2.2 Gastrointestinal Therapeutics Sales Area of Main Manufacturers
• 2.3 Trend of Concentration Rate

3 Global and Regional Gastrointestinal Therapeutics Market Status by Category

• 3.1 Gastrointestinal Therapeutics Category Introduction
  • 3.1.1 Oral
  • 3.1.2 Parenteral
• 3.2 Global Gastrointestinal Therapeutics Market by Category
• 3.3 North America: by Category
• 3.4 Europe: by Category
• 3.5 Asia Pacific: by Category
• 3.6 Central & South America: by Category
• 3.7 Middle East & Africa: by Category

4 Global and Regional Gastrointestinal Therapeutics Market Status by End User/Segment

• 4.1 Gastrointestinal Therapeutics Segment by End User/Segment
  • 4.1.1 IBD
  • 4.1.2 Irritable Bowel Syndrome (IBS)
• 4.2 Global Gastrointestinal Therapeutics Market by End User/Segment
• 4.3 North America: by End User/Segment
• 4.4 Europe: by End User/Segment
• 4.5 Asia Pacific: by End User/Segment
• 4.6 Central & South America: by End User/Segment
• 4.7 Middle East & Africa: by End User/Segment

5 Global Gastrointestinal Therapeutics Market Status by Region

• 5.1 Global Gastrointestinal Therapeutics Market by Region
• 5.2 North America Gastrointestinal Therapeutics Market Status
• 5.3 Europe Gastrointestinal Therapeutics Market Status
• 5.4 Asia Pacific Gastrointestinal Therapeutics Market Status
• 5.5 Central & South America Gastrointestinal Therapeutics Market Status
• 5.6 Middle East & Africa Gastrointestinal Therapeutics Market Status

6 North America Gastrointestinal Therapeutics Market Status

• 6.1 North America Gastrointestinal Therapeutics Market by Country
• 6.2 United States
• 6.3 Canada
• 6.4 Mexico

7 Europe Gastrointestinal Therapeutics Market Status

• 7.1 Europe Gastrointestinal Therapeutics Market by Country
• 7.2 Germany
• 7.3 France
• 7.4 UK
• 7.5 Italy
• 7.6 Russia
• 7.7 Spain

8 Asia Pacific Gastrointestinal Therapeutics Market Status

• 8.1 Asia Pacific Gastrointestinal Therapeutics Market by Country
• 8.2 China
• 8.3 Japan
• 8.4 Korea
• 8.5 Southeast Asia
• 8.6 India
• 8.7 Australasia

9 Central & South America Gastrointestinal Therapeutics Market Status

• 9.1 Central & South America Gastrointestinal Therapeutics Market by Country
• 9.2 Brazil
• 9.3 Argentina
• 9.4 Colombia

10 Middle East & Africa Gastrointestinal Therapeutics Market Status

• 10.1 Middle East & Africa Gastrointestinal Therapeutics Market by Country
• 10.2 Iran
• 10.3 Israel
• 10.4 Turkey
• 10.5 South Africa
• 10.8 Saudi Arabia

11 Major Downstream Customers Analysis

• 11.1 Customer One Analysis
• 11.2 Customer Two Analysis
• 11.3 Customer Three Analysis
• 11.4 Customer Four Analysis

12 Global Gastrointestinal Therapeutics Market Forecast by Category and by End User/Segment

• 12.1 Global Gastrointestinal Therapeutics Sales Value Forecast (2022-2027)
• 12.2 Global Gastrointestinal Therapeutics Forecast by Category
• 12.3 Global Gastrointestinal Therapeutics Forecast by End User/Segment

13 Global Gastrointestinal Therapeutics Market Forecast by Region/Country

• 13.1 Global Gastrointestinal Therapeutics Market Forecast by Region (2022-2027)
• 13.2 North America Market Forecast
• 13.3 Europe Market Forecast
• 13.4 Asia Pacific Market Forecast
• 13.5 Central & South America Market Forecast
• 13.6 Middle East & Africa Market Forecast

14 Key Participants Company Information

• 14.1 Tillotts Pharma
  • 14.1.1 Company Information
  • 14.1.2 Gastrointestinal Therapeutics Product Introduction
  • 14.1.3 Tillotts Pharma Gastrointestinal Therapeutics Sales Value, Gross Margin and Global Share (2019-2021)
  • 14.1.4 SWOT Analysis
• 14.2 Takeda
  • 14.2.1 Company Information
  • 14.2.2 Gastrointestinal Therapeutics Product Introduction
  • 14.2.3 Takeda Gastrointestinal Therapeutics Sales Value, Gross Margin and Global Share (2019-2021)
  • 14.2.4 SWOT Analysis
• 14.3 Takeda
  • 14.3.1 Company Information
  • 14.3.2 Gastrointestinal Therapeutics Product Introduction
  • 14.3.3 Takeda Gastrointestinal Therapeutics Sales Value, Gross Margin and Global Share (2019-2021)
  • 14.3.4 SWOT Analysis
• 14.4 Procter & Gamble
  • 14.4.1 Company Information
  • 14.4.2 Gastrointestinal Therapeutics Product Introduction
  • 14.4.3 Procter & Gamble Gastrointestinal Therapeutics Sales Value, Gross Margin and Global Share (2019-2021)
  • 14.4.4 SWOT Analysis
• 14.5 Pfizer
  • 14.5.1 Company Information
  • 14.5.2 Gastrointestinal Therapeutics Product Introduction
  • 14.5.3 Pfizer Gastrointestinal Therapeutics Sales Value, Gross Margin and Global Share (2019-2021)
  • 14.5.4 SWOT Analysis
• 14.6 Novartis
  • 14.6.1 Company Information
  • 14.6.2 Gastrointestinal Therapeutics Product Introduction
  • 14.6.3 Novartis Gastrointestinal Therapeutics Sales Value, Gross Margin and Global Share (2019-2021)
  • 14.6.4 SWOT Analysis
• 14.7 Merck
  • 14.7.1 Company Information
  • 14.7.2 Gastrointestinal Therapeutics Product Introduction
  • 14.7.3 Merck Gastrointestinal Therapeutics Sales Value, Gross Margin and Global Share (2019-2021)
  • 14.7.4 SWOT Analysis
• 14.8 Johnson & Johnson
  • 14.8.1 Company Information
  • 14.8.2 Gastrointestinal Therapeutics Product Introduction
  • 14.8.3 Johnson & Johnson Gastrointestinal Therapeutics Sales Value, Gross Margin and Global Share (2019-2021)
  • 14.8.4 SWOT Analysis
• 14.9 GlaxoSmithKline
  • 14.9.1 Company Information
  • 14.9.2 Gastrointestinal Therapeutics Product Introduction
  • 14.9.3 GlaxoSmithKline Gastrointestinal Therapeutics Sales Value, Gross Margin and Global Share (2019-2021)
  • 14.9.4 SWOT Analysis
• 14.10 F. Hoffmann-La Roche
  • 14.10.1 Company Information
  • 14.10.2 Gastrointestinal Therapeutics Product Introduction
  • 14.10.3 F. Hoffmann-La Roche Gastrointestinal Therapeutics Sales Value, Gross Margin and Global Share (2019-2021)
  • 14.10.4 SWOT Analysis
• 14.11 Eli Lilly
• 14.12 AstraZeneca
• 14.13 Amgen
• 14.14 Allergan
• 14.15 AbbVie

15 Conclusion

16 Methodology

Covid-19 has impacted the supply and demand status for many industries along the supply chain. In this report a comprehensive analysis of current global Gastrointestinal Therapeutics market in terms of demand and supply environment is provided, as well as price trend currently and in the next few years. Global leading players are profiled with their revenue, market share, profit margin, major product portfolio and SWOT analysis. This report also includes global and regional market size and forecast, major product development trend and typical downstream segment scenario, under the context of market drivers and inhibitors analysis. According to this survey, the global Gastrointestinal Therapeutics market is estimated to have reached $ xx million in 2020, and projected to grow at a CAGR of xx% to $ xx million in 2027.

Segmented by Category
Oral
Parenteral

Segmented by End User/Segment
IBD
Irritable Bowel Syndrome (IBS)

Segmented by Country
North America
United States
Canada
Mexico
Europe
Germany
France
UK
Italy
Russia
Spain
Asia Pacific
China
Japan
Korea
Southeast Asia
India
Australasia
Central & South America
Brazil
Argentina
Colombia
Middle East & Africa
Iran
Israel
Turkey
South Africa
Saudi Arabia

Key manufacturers included in this survey
Tillotts Pharma
Takeda
Takeda
Procter & Gamble
Pfizer
Novartis
Merck
Johnson & Johnson
GlaxoSmithKline
F. Hoffmann-La Roche
Eli Lilly
AstraZeneca
Amgen
Allergan
AbbVie